Since my analysis concluding 3 shots are required for the broad response needed against Omicron, and that #JnJers will need 2 shots of RNA, others like former Surgeon General @JeromeAdamsMD have reached the same conclusion
16M Americans are stuck in pre-Omicron limbo. We just need to admit J&J was like one shot of RNA, so they were behind 2xRNA-vaxxed and should be allowed to catch up. (And a 2nd J&J is not as good due to immunized clearance of the adenovirus vector)
Most #JnJers understand past mistakes of CDC and FDA on this and other topics have already degraded their credibility. This is why people are turning to writing articles to point out the problem. Credibility on this topic can only go up by addressing it usatoday.com/story/news/hea…
Study discussed in tweet #2 now published in Cell, concludes "recipients of Ad26.COV2.S (the J&J vaccine) may benefit from additional mRNA vaccine doses with the potential to further raise titers and broaden their neutralizing activity" doi.org/10.1016/j.cell…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
As @Merz mentioned Marin is one of the highest-vaxxed counties in CA. However it's not particularly young. The experience is "anecdotal" anyway but the PH officer relates it to past experience in the same location. It may serve as an example of what high vax rates can achieve.
@Merz The observation about low ICU rates is similar to what we've seen in London so far
While our attention was diverted by Omicron, FDA approved the viral mutagen molnupiravir (MOV) on the last business day before Christmas. The same time, Merck published that MOV doesn't reduce virus levels in the first 3 days. So patients will be shedding mutated virus for 3 days
I wrote in the Washington Post pointing out that widespread use of the drug increases the risk that we will create new immunoevasive variants. This could come from Delta; it may not be milder like Omicron. Since my piece is no longer browsable, I post it here as a public service
It's not just me. Most scientists or clinicians who know the data are worried. They include @JamesEKHildreth, Defense Health Agency director @peterweina, and former BARDA director @RickABright who were overruled either by FDA or by the prev admin on their MOV concerns
For a new year tried out a new mask, the 3M Aura N95 mask. Wow what a night and day difference. Didn't realize a mask could be this comfortable. Most amazing thing: speech comes through clearly.
My colleague @AbraarKaran is correct: CDC should be pushing better masks like these
These are $3 each and worth it. You can buy a 3pack (or 10pack) and rotate between them. On the 3 days off you let the mask air out to evaporate odors and let any viruses in them die off. More info on this thread.
Not only did HHS and CDC failed to push for mass manufacturing of these masks earlier (a problem since the previous administration when @RickABright was overruled on the matter) but CDC continued to push wrong or obsolete ideas about N95s
If we can avoid creating worse variants with molnupiravir, COVID19 can finally become like the flu in 2022.
1/n
The SA experience, mirrored in Western countries so far, suggests Omicron IFR is an order of magnitude lower than previous variants. This is due to preexisting immunity and lower virulence of Omicron.
More evidence a booster helps prevent you from catching Omicron. We knew that already from Pfizer but this study looks at risks within households, which is useful info as it provides an absolute rather than relative risk in a common situation
The chart ET posted is confusing, as it normalizes to the "fully vaxxed" state. Leaving aside the heterogeneity of this population (vaxxed at different times, and includes some unknown % with the less effective 1-shot J&J), normalizing to unvaxxed would be better. So I redid it.
As you can see the relative protection from intra-household infection for a boosted person is 48% for Omicron and 84% for Delta vs unvaxxed. 48% is lower than the 70% Pfizer measured, but that's expected for the higher-exposure household setting compared to community transmission
Thanks Dr. Hildreth for speaking out on the dangers of molnupiravir to "the health of the world". We need more people with foresight and integrity like you and @RickABright speaking up
Peter Weina @peterweina, director of the Defense Health Agency, also voted against molnupiravir at the 11/30 AMDAC meeting out of concern for generating new variants. The meeting has been poorly covered in most articles, but here's a good one below